Skip to main content
SpringerLink
Log in

Controversies in Evaluation and Management of Lipid Disorders in Diabetes

  • Chapter
Controversies in Treating Diabetes

Part of the book series: Contemporary Endocrinology ((COE))

  • 953 Accesses

Summary

Dyslipidemia is a key factors contributing to the high risk of cardiovascular disease (CVD) in diabetes and its management is of prime importance. However there are a number of controversies in this area which are dealt with in this chapter. One of these is the extent to which diabetes increases CVD risk, which turns out to vary considerably. A second question deals with the preferred dietary and other weight loss therapies and their benefits in dyslipidemic subjects. The third topic discussed deals with the question of “how low to go” with LDL-cholesterol lowering, and in a fourth issue the indications and approach to the use of second or third lipid-modifying agents in combination with statin therapy is discussed. Finally the controversial issue of whether apolipoprotein or lipoprotein subfraction measurements add to the value of the standard lipid profile is debated.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979; 241: 2035–2038.

    Article  PubMed  CAS  Google Scholar 

  2. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823–828.

    PubMed  CAS  Google Scholar 

  3. Solano MP, Goldberg RB. Management of diabetic dyslipidemia. Endocrinol Metab Clin North Am 2005; 34: 1–25.

    Article  Google Scholar 

  4. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. J Am Med Assoc 2004; 291: 335–342.

    Article  CAS  Google Scholar 

  5. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281: 1291–1297

    Article  PubMed  CAS  Google Scholar 

  6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), JAMA 2001; 285: 2486–2497.

    Article  Google Scholar 

  7. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234.

    Article  PubMed  CAS  Google Scholar 

  8. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000; 102: 1014–1019.

    PubMed  CAS  Google Scholar 

  9. Simons LA, Simons JS. Diabetes and coronary heart disease. N Engl J Med1998; 339: 1714–1716.

    Google Scholar 

  10. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med2001; 161: 1717–1723.

    Google Scholar 

  11. Lotufo PA, Gaziano M, Chae CU, et al. Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med 2001; 161: 242–247.

    Article  PubMed  CAS  Google Scholar 

  12. Cho E, Rimm EB, Stampfer MJ, et al. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol2002; 40: 954–960.

    Google Scholar 

  13. Lee CD, Folsom AR, Pankow JS, Brancati FL; Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004; 109: 855–860.

    Article  PubMed  Google Scholar 

  14. Hillier TA, Pedula KL. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care 2003; 26: 2999–3005.

    Article  PubMed  Google Scholar 

  15. Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF, Kahn CR. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987; 59: 750–755.

    Article  PubMed  CAS  Google Scholar 

  16. Centers for Disease Control and Prevention (CDC). Data & Trends. Available at http://www.cdc.gov/diabetes/statistics/age/source.htm.

    Google Scholar 

  17. Chaturvedi N, Jarrett J, Morrish N, Keen H, Fuller JH. Differences in mortality and morbidity in African Caribbean and European people with non-insulin-dependent diabetes mellitus: result of 20-year follow-up of a London cohort of a multinational study. BMJ 1996; 313: 848–852.

    PubMed  CAS  Google Scholar 

  18. Dijkstra, M. Klok, D. Hoogenhuyze van, HP Sauerwein, A. Berghout. Ischaemic heart disease in Turkish migrants with type 2 diabetes mellitus in the Netherlands: wait for the next generation? Neth J Med 2002; 60: 21–24.

    Google Scholar 

  19. Weijers RNM, Goldschmidt HMJ, Silberbusch J. Vascular complications in relation to ethnicity in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1997, 27: 182–188.

    Article  PubMed  CAS  Google Scholar 

  20. Hunt KJ, Williams K, Resendez RG, Hazuda HP, Haffner SM, Stern MP. All-cause and cardiovascular mortality among diabetic participants in the San Antonio Heart Study: evidence against the “Hispanic Paradox.” Diabetes Care 2002; 25: 1557–63.

    Article  PubMed  Google Scholar 

  21. Kittner SJ, White LR, Losonczy KG, Wolf PA, Hebel JR. Black-white differences in stroke incidence in a national sample. The contribution of hypertension and diabetes mellitus. JAMA 1990; 264: 1267–1270.

    Article  PubMed  CAS  Google Scholar 

  22. Stamler J, Vaccaro O, Neaton J, Wentworth D; Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors and 12 year cardiovascular mortality for men screened in the Multiple Risk Factors Intervention Trial. Diabetes Care 1993; 16: 434–444.

    Google Scholar 

  23. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 12; 412–419.

    Google Scholar 

  24. Pavkov ME, Bennett PH, Sievers ML, Krakoff J, Williams DE, Knowler WC, Nelson RG. Predominant effect of kidney disease on mortality in Pima Indians with or without type 2 diabetes. Kidney Int 2005; 68: 1267–1274.

    Article  PubMed  Google Scholar 

  25. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997; 15: 1413–8.

    Article  Google Scholar 

  26. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346; 393–403.

    Google Scholar 

  27. Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams T, Williams M, Gracely EJ, Stern L. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003; 348: 2074–2081.

    Article  PubMed  CAS  Google Scholar 

  28. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, Clark NG. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004; 27: 2067–2073.

    Article  PubMed  Google Scholar 

  29. US Department of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General: Centers for Disease Control and Prevention and National Center for Chronic Disease Prevention and Health Promotion. Washington, DC: US Government Printing Office, 1996.

    Google Scholar 

  30. American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2003; 26: S51–S61

    Google Scholar 

  31. Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S, Kris-Etherton PM. Effects of the National Cholesterol Education Program’s step I and II dietary intervention program on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr 1999; 69: 632–646.

    PubMed  CAS  Google Scholar 

  32. Temme EH, Van Hoydonck PG, Schouten EG, Kesteloot H. Effects of a plant sterol-enriched spread on serum lipids and lipoproteins in mildly hypercholesterolemic subjects. Acta Cardiol 2002; 57: 111–115.

    Article  PubMed  Google Scholar 

  33. Gylling H, Miettinen TA. Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetologia 1994; 37: 773–780.

    Article  PubMed  CAS  Google Scholar 

  34. Chandalia M, Garg A, Lutjohann D, von Bergmann K, Grundy SM, Brinkley LJ. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Eng J Med 2000; 342: 1392–1398.

    Google Scholar 

  35. Anderson JW, Allgood LD, Turner J, Oeltgen PR, Daggy BP. Effects of Psyllium on glucose and serum lipid responses in men with type 2 diabetes and hypercholesterolemia. Am J Clin Nutr 1999; 70: 466–473.

    PubMed  CAS  Google Scholar 

  36. Turley ML, Skeaff CM, Mann JI, Cox B. The effect of a low-fat, high-carbohydrate diet on serum high density lipoprotein cholesterol and triglyceride. Eur J Clin Nutr 1998; 52: 728–732.

    Article  PubMed  CAS  Google Scholar 

  37. Garg A. High-monounsaturated-fat diets for patients with diabetes mellitus: a meta-analysis. Am J Clin Nutr 1998; 67: 577S–582S.

    PubMed  CAS  Google Scholar 

  38. Bravata DM, Sanders L, Huang J, Krumholz HM, Olkin I, Gardner CD, Bravata DM. Efficacy and safety of low-carbohydrate diets. A systematic review. JAMA 2003; 289: 1837–1850.

    Article  PubMed  CAS  Google Scholar 

  39. Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 2005; 28: 942–949.

    Article  PubMed  CAS  Google Scholar 

  40. O’Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev 2004; 5: 51–68.

    Article  PubMed  CAS  Google Scholar 

  41. Pinkney J, Kerrigan D. Current status of bariatric surgery in the treatment of type 2 diabetes. Obes Rev 2004; 5: 69–78.

    Article  PubMed  CAS  Google Scholar 

  42. Goldberg RB, Capuzzi D. Lipid disorders in type 1 and type 2 diabetes. Clin Lab Med 2001; 1: 147–172.

    Google Scholar 

  43. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823–828.

    PubMed  CAS  Google Scholar 

  44. Heart Protection Study Collaborative Group. MCR/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7–22.

    Article  Google Scholar 

  45. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004; 364: 685–696.

    Article  PubMed  CAS  Google Scholar 

  46. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–1504

    Article  PubMed  CAS  Google Scholar 

  47. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program; Coordinating Committee of the National Cholesterol Education Program: National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–239.

    Article  PubMed  Google Scholar 

  48. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435.

    Article  PubMed  CAS  Google Scholar 

  49. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006; 29: 1220–1226.

    Article  PubMed  CAS  Google Scholar 

  50. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP; Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409–2415.

    Google Scholar 

  51. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2006; 29(Suppl 1); S4–S42.

    Google Scholar 

  52. Gracia PJ. Pleiotropic effects of statins: moving beyond cholesterol control. Curr Atheroscler Rep 2005; 7: 34–39.

    Article  Google Scholar 

  53. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study a randomized controlled trial. JAMA 2001; 285: 1711–1718.

    Article  PubMed  CAS  Google Scholar 

  54. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959–1965.

    Article  PubMed  CAS  Google Scholar 

  55. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352(1): 20–28.

    Article  PubMed  CAS  Google Scholar 

  56. Ridker PM; JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003; 108: 2292–2297.

    Article  PubMed  Google Scholar 

  57. Ford E. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999; 22: 1971–1977.

    Article  PubMed  CAS  Google Scholar 

  58. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004; 44: 2293–2300.

    Article  PubMed  CAS  Google Scholar 

  59. Alexander CM, Landsman PB, Teutsch SM, Haffner SM; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-1214.

    Google Scholar 

  60. Cowie CC, Harris ML. Physical and Metabolic Characteristics of Persons with Diabetes. Diabetes in America. 2nd ed. National Institutes of Health, Bethesda, MD, USA 1995: 117–164.

    Google Scholar 

  61. Manley SE, Frighi V, Stratton E, et al. U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 1997; 20: 1683–1687.

    Article  Google Scholar 

  62. Feingold KR, Grunfeld C, Pang M, et al. LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes. Arterioscler Thromb Vasc Biol 1992; 12: 1496–1502.

    CAS  Google Scholar 

  63. The Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein and hemostatic factors at baseline in the Diabetes Prevention Program. Diabetes Care 2005; 28: 2472–2479.

    Google Scholar 

  64. Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003; 91: 1304–1310.

    Article  PubMed  CAS  Google Scholar 

  65. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002; 1198–1202.

    Google Scholar 

  66. Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 2002; 51: 2377–2386

    Article  PubMed  CAS  Google Scholar 

  67. Emanuele N, Azad N, Abraira C, Henderson W, Colwell J, Levin S, Nuttall F, Comstock J, Sawin C, Silbert C, Marcovina S, Lee HS. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in type II diabetes mellitus. Arch Intern Med 1998; 18: 2485–2490.

    Article  Google Scholar 

  68. Palumbo PJ. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998; 12: 110–119.

    Article  PubMed  CAS  Google Scholar 

  69. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547–1554.

    Article  PubMed  CAS  Google Scholar 

  70. Scharnagl H, Schinker R, Gierens H, Nauck M, Wieland H, Marz W. Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol 2001; 62: 1545–1555.

    Article  PubMed  CAS  Google Scholar 

  71. Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002; 51: 334–342.

    Article  PubMed  CAS  Google Scholar 

  72. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512–3517.

    Article  PubMed  CAS  Google Scholar 

  73. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care 2005; 28: 1916–1921.

    Article  PubMed  Google Scholar 

  74. Robins SJ. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? Curr Opin Lipidol 2003; 14: 575–583.

    Article  PubMed  CAS  Google Scholar 

  75. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292–2300.

    Article  PubMed  CAS  Google Scholar 

  76. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820–825.

    Article  PubMed  CAS  Google Scholar 

  77. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410–418.

    Article  PubMed  CAS  Google Scholar 

  78. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002; 162: 2597–2604

    Article  PubMed  CAS  Google Scholar 

  79. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000; 102: 21–27.

    Google Scholar 

  80. The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849–1861

    Google Scholar 

  81. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 2001; 357: 905–910.

    Google Scholar 

  82. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71–75.

    Article  PubMed  CAS  Google Scholar 

  83. Tal A, Rajeshawari M, Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J 1997; 90: 546–547.

    PubMed  CAS  Google Scholar 

  84. Pogson G, Kindred L, Carper B. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol 1999; 83: 1146.

    Google Scholar 

  85. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998; 81: 368–369.

    Article  PubMed  CAS  Google Scholar 

  86. Ellen RL, McPherson R. Long term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998; 81: 60B–65B.

    Google Scholar 

  87. Iliadis EA, Rosenson RS. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol 1999; 22: 25–28.

    Article  PubMed  CAS  Google Scholar 

  88. Murdock DK, Murdock AK, Murdock RW. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J 1999; 138: 151–155

    Article  PubMed  CAS  Google Scholar 

  89. Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM. Effects of adding fenofibrate (200mg/day) to simvastatin (10mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003; 91: 956–960.

    Article  PubMed  CAS  Google Scholar 

  90. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH Pearson PG, Baillie TA. Mechanistic studies on metabolic interactions between gemfibrozil and statins. Pharmacol Exp Ther 2002; 301: 1042–1051.

    Article  CAS  Google Scholar 

  91. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30: 1280–1287.

    Article  PubMed  CAS  Google Scholar 

  92. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95: 120–122.

    Article  PubMed  CAS  Google Scholar 

  93. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41: 1–91.

    Google Scholar 

  94. Shepherd J, Betteridge J, Van Gaal L; European Consensus Panel. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin 2005; 21: 665–682

    Article  PubMed  CAS  Google Scholar 

  95. Carlson LA, Hamsten A, Asplaund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med 1989; 226: 271–276.

    PubMed  CAS  Google Scholar 

  96. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 1992; 95: 69–76.

    Article  PubMed  CAS  Google Scholar 

  97. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360–381.

    Google Scholar 

  98. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005; 95: 254–257.

    Article  PubMed  CAS  Google Scholar 

  99. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for prevent of coronary disease. N Eng J Med 2001; 345: 1583–1592.

    Article  CAS  Google Scholar 

  100. Omar MA, Wilson JP, Cox TS: Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096–1107.

    Article  PubMed  CAS  Google Scholar 

  101. Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study. A randomized trial. JAMA 2000; 284: 1263–1270.

    Article  PubMed  CAS  Google Scholar 

  102. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP; Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med 2002; 162: 1568–1576.

    Article  PubMed  CAS  Google Scholar 

  103. Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE. Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care 1998; 21: 494–500.

    Article  PubMed  CAS  Google Scholar 

  104. Woodman RJ, Mori TA, Burke V, Puddey IB, Barden A, Watts GF, Beilin LJ. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002; 76: 1007–1015.

    PubMed  CAS  Google Scholar 

  105. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K. Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007; 369:1090–1098.

    Article  PubMed  CAS  Google Scholar 

  106. Kris-Etherton PM, Harris WS, Appel LJ; AHA Nutrition Committee; American Heart Association. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106(21): 2747–2757.

    Google Scholar 

  107. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein b as targets of lipid-lowering therapy. Circulation 2002; 106: 2526–2529.

    Article  PubMed  Google Scholar 

  108. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361: 777–780.

    Google Scholar 

  109. Williams K, Sniderman AD, Sattar N, et al. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation2003; 108: 2312–2316.

    Google Scholar 

  110. Sniderman AD, St Pierre AC, Cantin B, et al. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol2003; 91: 1173–1177.

    Google Scholar 

  111. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005; 294: 326–333

    Article  PubMed  CAS  Google Scholar 

  112. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005; 112: 3375–3383.

    Article  PubMed  CAS  Google Scholar 

  113. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 453–462.

    Article  PubMed  CAS  Google Scholar 

  114. Wägner AM, Pérez A, Zapico E, Ordóñez-Llanos J. Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. Diabetes Care 2003; 26: 2048–2051.

    Article  PubMed  Google Scholar 

  115. van Lennep JE, Westerveld HT, van Lennep HW, et al. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol2000; 20: 2408–2413.

    PubMed  Google Scholar 

  116. Genest J, Frohlich J, Fodor G, McPherson R; Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003; 169: 921–924.

    PubMed  Google Scholar 

  117. Lada AT, Rudel LL. Associations of low density lipoprotein particle composition with atherogenicity. Curr Opin Lipidol 2004; 15: 19–24.

    Article  PubMed  CAS  Google Scholar 

  118. Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 2004; 6: 381–387.

    Article  PubMed  Google Scholar 

  119. Blake GJ, Otvos JD, Rifai N, Ridker PM. LDL particle concentration and size as determined by NMR spectroscopy as predictors of cardiovascular disease in women. Circulation 2002; 106: 1930–1937.

    Article  PubMed  CAS  Google Scholar 

  120. Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, D’Agostino RB, Vasan RS, Robins SJ. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006; 113: 20–29.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Ronald B. Goldberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Diabetes, and Bone Disease, Department of Medicine, Mount Sinai School of Medicine, New York, NY

    Derek LeRoith MD PhD

  2. Diabetes Research Institute Department of Medicine, Eastern Virginia Medical School The Leonard Strelitz Diabetes Institutes, Norfolk, VA

    Aaron I. Vinik MD PhD FCP FACP

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press

About this chapter

Cite this chapter

MD, R.B.G. (2008). Controversies in Evaluation and Management of Lipid Disorders in Diabetes. In: LeRoith, D., Vinik, A.I. (eds) Controversies in Treating Diabetes. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-59745-572-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-572-5_15

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-708-2

  • Online ISBN: 978-1-59745-572-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation